DBV Technologies S.A. (LON:0QAJ)

Market Cap	779.98M +354.1%
Revenue (ttm)	4.34M +61.9%
Net Income	-126.81M
EPS	-0.57
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,100
Open	3.300
Previous Close	3.370
Day's Range	3.170 - 3.314
52-Week Range	1.320 - 4.460
Beta	-0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 29, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 161
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAJ

Financial Performance

In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.

Financial numbers in USD